Industry-Specific Ratio Guidelines
Learn which ratios matter most for different industries and appropriate benchmarks for each sector.
Learning Objectives
- Identify key ratios for technology companies
- Apply financial services-specific metrics
- Evaluate retail and consumer companies
- Analyze industrial and healthcare sectors
Industry-Specific Ratio Guidelines#
Not all ratios apply equally to all industries. A bank's P/E of 10 means something different than a software company's P/E of 10. Understanding industry-specific metrics and benchmarks is essential for accurate analysis.
Key Principle: Always benchmark against industry peers, not the broader market. A 5% net margin is terrible for software but excellent for grocery retail.
Technology Companies#
Software/SaaS Companies#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Revenue Growth | Primary driver of value | > 20% (growth stage) |
| Gross Margin | Software economics | > 70% |
| Operating Margin | Path to profitability | > 20% (mature) |
| Rule of 40 | Growth + Margin balance | > 40% |
| Net Revenue Retention | Customer stickiness | > 100% |
Rule of 40
Rule of 40 = Revenue Growth % + Operating Margin %
A SaaS company with 30% growth and 15% margin = 45% (passing). This metric balances growth investment against profitability.
Valuation Metrics:
- EV/Revenue (common for high-growth)
- EV/EBITDA (for profitable companies)
- P/E less relevant until profitable
Hardware/Semiconductor#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Gross Margin | Product differentiation | 40-60% |
| R&D as % of Revenue | Innovation investment | 15-25% |
| Inventory Turnover | Cycle time | 4-8x |
| Cash Conversion Cycle | Working capital efficiency | < 60 days |
Watch For: Inventory buildup (obsolescence risk), cyclical demand patterns
Financial Services#
Banks#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| P/Tangible Book | Asset-based valuation | 1.0-2.0x |
| ROE | Return on equity | > 10% |
| Net Interest Margin | Core profitability | 2.5-3.5% |
| Efficiency Ratio | Cost control | < 60% |
| CET1 Ratio | Capital strength | > 10% |
| NPL Ratio | Loan quality | < 2% |
Banks Are Different
Standard P/E analysis doesn't work well for banks. Use P/Tangible Book Value as the primary valuation metric, and focus on ROE, NIM, and loan quality ratios.
Avoid If:
- NPL ratio rising significantly
- Net Interest Margin compressing
- Efficiency ratio > 70%
Insurance Companies#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Combined Ratio | Underwriting profitability | < 100% |
| P/Book Value | Asset-based valuation | 1.0-1.5x |
| ROE | Overall profitability | > 10% |
| Investment Yield | Portfolio returns | Varies by type |
Combined Ratio < 100% means the company profits from underwriting before investment income.
REITs#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| FFO (Funds From Operations) | Cash flow proxy | Growing |
| P/FFO | REIT valuation | 12-20x |
| Dividend Yield | Income return | 4-7% |
| Occupancy Rate | Asset utilization | > 90% |
| Debt/EBITDA | Leverage | < 6x |
FFO = Net Income + Depreciation - Gains on Property Sales
REITs use FFO instead of EPS because real estate depreciation doesn't reflect actual property value decline.
Retail and Consumer#
Retail (Grocery, Department Stores)#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Same-Store Sales | Organic growth | Positive |
| Gross Margin | Pricing power | 20-35% |
| Inventory Turnover | Merchandise velocity | 4-12x (varies) |
| Sales per Sq Ft | Space productivity | Varies by format |
| Current Ratio | May be < 1 | 0.8-1.2 (normal) |
Retail-Specific Notes:
- Low current ratios are normal (fast inventory turnover)
- Same-store sales growth matters more than total revenue growth
- Online vs. physical mix increasingly important
Consumer Staples#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Gross Margin | Brand pricing power | 40-60% |
| Dividend Yield | Income stability | 2-4% |
| ROE | Capital efficiency | 15-25% |
| Revenue Growth | Low but stable | 2-5% |
Characteristics: Defensive, stable earnings, strong dividends, low growth expectations
Consumer Discretionary#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Revenue Growth | Demand sensitivity | Cyclical |
| Operating Margin | Cost management | 10-15% |
| Debt/EBITDA | Recession resilience | < 2.5x |
| P/E | Cyclical valuation | Varies with cycle |
Watch For: High leverage before recessions, inventory buildup during slowdowns
Industrial and Manufacturing#
Industrials#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Fixed Asset Turnover | Equipment utilization | > 2.0x |
| Operating Margin | Manufacturing efficiency | 10-18% |
| Backlog/Revenue | Visibility | > 1x |
| Debt/EBITDA | Cyclical cushion | < 2.5x |
| Free Cash Flow Conversion | Earnings quality | > 80% |
Cyclical Considerations:
- Compare to mid-cycle earnings, not peak
- Check backlog trends for demand visibility
- Conservative leverage essential for downturns
Aerospace & Defense#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Backlog Years | Contract visibility | 2-5 years |
| Operating Margin | Program profitability | 10-15% |
| FCF Conversion | Cash generation | > 90% |
| Book-to-Bill | Order momentum | > 1.0x |
Healthcare and Pharma#
Pharmaceuticals#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| R&D as % Revenue | Pipeline investment | 15-25% |
| Gross Margin | Drug pricing power | > 70% |
| Patent Cliff Exposure | Revenue risk | < 30% in 3 years |
| Pipeline Value | Future growth | Qualitative |
Key Risks: Patent expirations, drug pricing pressure, clinical trial failures
Medical Devices#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Gross Margin | Product value | 60-70% |
| R&D Spending | Innovation | 8-12% |
| Revenue Growth | Market share | 5-10% |
| Operating Margin | Scale efficiency | 20-25% |
Biotech#
| Key Metric | Why It Matters | Good Benchmark |
|---|---|---|
| Cash Runway | Survival | > 2 years |
| Pipeline Progress | Value creation | Advancing |
| P/E | Usually N/A | Not applicable |
| EV vs. Cash | Market's pipeline value | Premium = optimism |
Biotech Caution
Most biotech companies are pre-revenue. Traditional ratios don't apply. Focus on: cash runway, pipeline milestones, partnership deals, and scientific merit. This is specialized analysis.
Quick Reference: Industry Ratio Focus#
| Industry | Primary Ratios | Secondary Ratios |
|---|---|---|
| Software | Revenue Growth, Gross Margin, Rule of 40 | EV/Revenue, FCF |
| Banks | P/TBV, ROE, NIM, NPL Ratio | Efficiency Ratio, CET1 |
| REITs | P/FFO, Dividend Yield, Occupancy | Debt/EBITDA |
| Retail | Same-Store Sales, Inventory Turnover | Gross Margin |
| Industrials | Fixed Asset Turnover, Backlog | Operating Margin, FCF |
| Pharma | R&D %, Gross Margin, Patent Cliff | Pipeline value |
Key Takeaways
- Software: Focus on growth, gross margin, Rule of 40 (Growth% + Margin%)
- Banks: Use P/Tangible Book, ROE, Net Interest Margin, NPL ratios
- REITs: Use FFO (not EPS), P/FFO, dividend yield, occupancy rates
- Retail: Same-store sales and inventory turnover matter most; low current ratio is normal
- Industrials: Fixed asset turnover, backlog visibility, conservative leverage
- Pharma: R&D spending, patent cliff exposure, pipeline value
- Biotech: Cash runway and pipeline progress—traditional ratios don't apply
- Always benchmark within industry—a 5% margin can be excellent or terrible depending on sector